Filed a patent of CNS-specific peptides & AAV variants
Signed a MOU with Modalis Therapeutics Corporation, jointly developing a XOB031-mediated AAV gene therapy for Alzheimer’s disease
ODD request of GXC-301, a therapeutic agent for Lafora disease, granted by US FDA
Selected as a ‘2024 UNICORN’ and raised UDS 2M (Global Unicorn Project by Ministry of SMEs and Startups)
RPDD request of GXC-301, a therapeutic agent for Lafora disease, granted by US FDA
InsightMiner™, won a prize and a award at AI Rocket Launcher Day Season4, 2024 AI EXPO
A ‘co-developing’ Alzheimer’s disease therapeutic program with Hanyang Univ., funded by a governmental global R&D program from KHIDI
MOU signed with AJOU MBD T2B Center
Change of corporate name to GENIXCURE Inc.
Filed 4 patents of AI-based cell-specific peptides & AAVs (featuring 60 vectors)
Made a presentation of GXC-301(Lafora disease) preclinical data at 2023 Lafora Disease Science Symposium in Bologna, Italy
Filed a patent application for GXC301, a therapeutic agent for Lafora disease
Made a presentation of an AAV program at ISCT 2023 in Paris (Collaborative research with Samsung Seoul Hospital)
Signed MOUs with Kyungdong Pharmaceutical Co., Ltd. for GMP CDMO and L/O
Signed Research and Development Agreement with ToolGen
Inno-Biz Certification (Minister of Small and Medium Venture Business)
Participation in R&D projects to foster research-oriented hospitals (supervisor: Samsung Seoul Hospital)
Series A fundraising
TF launched for InsightMiner™ 1.0
Signed a MOU with MedySapiens
GXC101 funded by a government R&D program by KHIDI
GXC301 funded by a government R&D program by Ministry of SMEs and Startups
Awarded ‘Appreciation of Technology Commercialization & Entrepreneurship’ from Ministry of Health and Welfare
GXC101 funded 1M by a government R&D program by Ministry of Health and Welfare
Certification of venture companies
GXC-101 patent registered in the US
Certification of corporate research institutes
GXC-101 in licensing from IBS & DGIST
Founded